X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs ASTRAZENECA PHARMA - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. ASTRAZENECA PHARMA FRESENIUS KABI ONCO./
ASTRAZENECA PHARMA
 
P/E (TTM) x 22.1 155.7 14.2% View Chart
P/BV x 3.1 24.2 12.9% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 FRESENIUS KABI ONCO.   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
ASTRAZENECA PHARMA
Mar-14
FRESENIUS KABI ONCO./
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs1761,285 13.7%   
Low Rs79634 12.4%   
Sales per share (Unadj.) Rs37.7189.6 19.9%  
Earnings per share (Unadj.) Rs5.1-0.2 -2,501.6%  
Cash flow per share (Unadj.) Rs6.73.8 174.9%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs42.568.6 62.0%  
Shares outstanding (eoy) m158.2325.00 632.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.45.1 66.7%   
Avg P/E ratio x25.0-4,712.7 -0.5%  
P/CF ratio (eoy) x18.9249.6 7.6%  
Price / Book Value ratio x3.014.0 21.4%  
Dividend payout %00-   
Avg Mkt Cap Rs m20,13523,988 83.9%   
No. of employees `0001.21.6 73.9%   
Total wages/salary Rs m7031,605 43.8%   
Avg. sales/employee Rs Th5,176.23,040.2 170.3%   
Avg. wages/employee Rs Th610.41,029.2 59.3%   
Avg. net profit/employee Rs Th699.6-3.3 -21,426.8%   
INCOME DATA
Net Sales Rs m5,9634,740 125.8%  
Other income Rs m1892 19.5%   
Total revenues Rs m5,9814,832 123.8%   
Gross profit Rs m1,430-130 -1,101.8%  
Depreciation Rs m258101 254.8%   
Interest Rs m-260-   
Profit before tax Rs m1,216-139 -875.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-68139 -49.0%   
Tax Rs m3425 6,723.0%   
Profit after tax Rs m806-5 -15,833.0%  
Gross profit margin %24.0-2.7 -875.7%  
Effective tax rate %28.1-3.7 -767.8%   
Net profit margin %13.5-0.1 -12,584.9%  
BALANCE SHEET DATA
Current assets Rs m5,1022,726 187.1%   
Current liabilities Rs m2,3852,435 98.0%   
Net working cap to sales %45.66.1 740.9%  
Current ratio x2.11.1 191.0%  
Inventory Days Days15074 203.4%  
Debtors Days Days11341 277.9%  
Net fixed assets Rs m5,1481,035 497.3%   
Share capital Rs m15850 316.4%   
"Free" reserves Rs m6,556942 695.6%   
Net worth Rs m6,7321,716 392.3%   
Long term debt Rs m9520-   
Total assets Rs m10,3884,156 250.0%  
Interest coverage x-45.8NM-  
Debt to equity ratio x0.10-  
Sales to assets ratio x0.61.1 50.3%   
Return on assets %7.5-0.1 -6,130.1%  
Return on equity %12.0-0.3 -4,036.0%  
Return on capital %14.60-  
Exports to sales %74.55.7 1,306.3%   
Imports to sales %24.86.5 383.4%   
Exports (fob) Rs m4,441270 1,643.4%   
Imports (cif) Rs m1,477306 482.3%   
Fx inflow Rs m5,298375 1,414.2%   
Fx outflow Rs m1,772470 376.9%   
Net fx Rs m3,525-96 -3,689.6%   
CASH FLOW
From Operations Rs m1,274-8 -15,729.6%  
From Investments Rs m-1,204-146 826.5%  
From Financial Activity Rs m-196862 -22.7%  
Net Cashflow Rs m-126709 -17.8%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 81.0 75.0 108.0%  
Indian inst/Mut Fund % 0.3 0.3 100.0%  
FIIs % 9.6 15.7 61.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 9.1 100.0%  
Shareholders   42,599 12,856 331.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   GSK PHARMA  NATCO PHARMA  DIVIS LABORATORIES  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  

Compare FRESENIUS KABI ONCO. With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Macroeconomic Cues Guide the Markets This Week(Podcast)

Global markets remained in pressure this week. Pound fell sharply as risk of chaotic Brexit rose.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 10.3% (Quarterly Result Update)

Aug 21, 2018 | Updated on Aug 21, 2018

For the quarter ended June 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 64 m (up 10.3% YoY). Sales on the other hand came in at Rs 2 bn (up 25.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 212.1% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 32 m (down 212.1% YoY). Sales on the other hand came in at Rs 2 bn (up 35.1% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 5-YR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS